Pharming Group N.V. (PHAR)
NasdaqGM · USD · Healthcare · Biotechnology
$11.90 (+6.25%) as of
Key statistics
- Market cap
- 842.26M
- P/E (TTM)
- 91.54
- Forward P/E
- 30.91
- EPS (TTM)
- 0.13
- Dividend yield
- 0.00%
- 52-week range
- 9.11 – 21.34
- Beta
- 0.07
- Revenue (TTM)
- 366.48M
- Profit margin
- 2.54%
- Analyst target
- $34.35
- Volume
- 43.44k
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Leiden, Netherlands
- Employees
- 407
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.